Clinical Trial Update: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating anlotinib hydrochloride capsule with AK105 in advanced gastric and gastro-oesophageal junction adenocarcinoma is in progress with unkno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastro-oesophageal Junction Adenocarcinoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib hydrochloride capsule (Anlotinib hydrochloride)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | Phase 3 | Status: UNKNOWN